Medisafe 1 Technologies Corp. seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. The company’s patented technology is a medical assembly with a locking mechanism that is intended to ensure that a substance cannot be released from a hypodermic needle without positive pre-matching between the substance and its intended patient.
The company today announced positive developments relating to the production of a prototype of its locking device technology. The prototype has successfully passed Medisafe 1 Technologies’ preliminary testing phase. The tests confirm the potential of the prototype to significantly reduce preventable drug-related injuries in hospitals.
Medisafe’s patented locking device works in conjunction with a bar-code reader and database system. The device uses a barcoded system to electronically confirm whether the syringe held by a medical practitioner contains the correct medication and dosage that has been prescribed to a particular patient, before allowing that medication to be physically administered.
There is a definite market for Medisafe’s device. Medication administration errors in hospitals cause 400,000 preventable drug-related injuries and 70,000 deaths each year. The company estimates that the total potential market for its patented technologies could exceed $1 billion per year.
Let us hear your thoughts below:
